In this prospective study, we have examined monocyte count and mRNA expression of S100A9 and S100A12 in PBMCs as well as corresponding circulating protein levels in blood samples from prostate cancer patients, and report higher levels in patients with metastases compared to high-risk patients without metastases. This evidence concerns the gene S100A9 and prostate cancer.